Evidence map›Paper›PMID 42211722›Full record

ArticleBioactive materials2026

An immuno-chemotherapeutic bone scaffold for tumor eradication and bone regeneration in drug-resistant osteosarcoma.

Zuyun Yan, Yiwen He, Jin Zeng, Tao He, Dongcheng Xu, Xin Wu, Hao Zhou, Wei Tan, Xiaofang Zang, Youwen Deng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zuyun YanDepartment of Spine Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Yiwen HeDepartment of Spine Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Jin ZengDepartment of Spine Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Tao HeDepartment of Spine Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Dongcheng XuDepartment of Spine Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Xin WuDepartment of Spine Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Hao ZhouDepartment of Spine Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Wei TanDepartment of Spine Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Xiaofang ZangDepartment of Spine Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Youwen DengDepartment of Spine Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Postoperative management of osteosarcoma remains hindered by several critical challenges, including platinum-based chemoresistance, insufficient antitumor immune responses, and the difficulty of synchronously repairing large bone defects. Addressing these issues requires strategies capable of coordinating tumor eradication, immune modulation, and bone regeneration within the dynamic postoperative microenvironment. In this study, we developed a near-infrared (NIR)-responsive intelligent composite bone scaffold that integrates a reducible platinum (IV) prodrug (Pt (IV)) and cucurbitacin B (CuB) via hollow mesoporous silica and polydopamine interfacial engineering, enabling dual responsiveness to tumor-associated cues and exogenous photonic stimulation. Mechanistically, controlled CuB release suppresses DNA damage repair, amplifies Pt (IV)-induced DNA damage, and reverses platinum resistance, while the combined action of Pt (IV) and CuB induces immunogenic cell death and activates the cGAS-STING pathway, thereby remodeling an antitumor immune microenvironment. Concurrently, sustained Si

Indexed as

Bone regenerationCucurbitacin BOsteosarcomaPhotothermal therapyPt (IV) prodrugs

Identifiers

PMID42211722
PMCPMC13214273

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.